Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation

Pyxis Oncology, Inc.

Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.
Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.
All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.
One-year post-separation non-solicitation and mutual non-disparagement covenants apply.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lara Sullivan

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2026-04-29
Filed: April 30, 2026, 7:59 PM ET

Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.

Departed

Lara Sullivan

Chief Executive Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2026-04-29
Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lara Sullivan resigned as Director at Pyxis Oncology, Inc..

Action: resigned
Role: Director

Exact text from the filing

Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..

Action: separated
Role: Chief Executive Officer

Exact text from the filing

On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-193940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.